Unecritinib（Cat No.:I043360）is a potent, oral, small-molecule inhibitor targeting multiple receptor tyrosine kinases, including EGFR (epidermal growth factor receptor) and ALK (anaplastic lymphoma kinase). It has shown significant promise in preclinical and clinical studies, particularly for the treatment of cancers with EGFR mutations and ALK-positive non-small cell lung cancer (NSCLC). By inhibiting these key signaling pathways involved in tumor growth and survival, unecritinib aims to suppress cancer progression and overcome resistance to other targeted therapies. Ongoing research continues to evaluate its efficacy, safety, and potential for broader cancer indications.